Research and Markets: Determine the Impact of the ENHANCE Study on Vytorin and Zetia Use
DUBLIN, Ireland--(BUSINESS WIRE)--Jun 23, 2008 - Research and Markets (http://www.researchandmarkets.com/research/4e90d7/vytorin_wave_two) has announced the addition of the "Vytorin: Wave Two - Impact of ENHANCE Trial" report to their offering.A Survey of One-Hundred Three US-based PCP's and Cardiologists
Deliverable: Survey with key findings.
Study Description:
Topic: Vytorin: Wave Two -- Impact of ENHANCE Trial
Respondent Type: Physicians
Specialties Covered: Primary Care and Cardiology
Region: United States Only
Methodology
- Online survey, self-administered via a Panel Intelligence website
- Duration: 10 minutes
- Size: 72 PCP's and 31 Cardiologists for 103 respondents
- Fielding Dates: April 1st to April 4th, 2008
Inclusion Criteria and Respondent Demographics:
- US-based
- 2 to 30 years of experience post-training
- Minimum of 75% professional time spent in clinical practice
- Writes at least 20 prescriptions for Zetia and Vytorin (combined) in an average month
Companies Mentioned:
- AstraZeneca
- Pfizer
- Merck/Schering-Plough Pharmaceuticals
- Merck & Co
For more information visit http://www.researchandmarkets.com/research/4e90d7/vytorin_wave_two
Contact
Research and Markets
Laura Wood
Senior Manager
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com
Posted: June 2008
